Celldex Therapeutics Inc (NAS:CLDX)
$ 36.92 0.6 (1.65%) Market Cap: 2.43 Bil Enterprise Value: 1.61 Bil PE Ratio: 0 PB Ratio: 2.90 GF Score: 62/100

Celldex Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 01:00PM GMT
Release Date Price: $35.23 (+0.74%)
Chris Howerton
(Trades, Portfolio), Inc. - Moderator

We have the Celldex team here, and we're hoping to talk about a little bit of KIT, so let's get started. Anthony, maybe you could get us started in terms of barzolvolimab? And where do you see that in terms of the KIT space?

Questions & Answers

Anthony Marucci
Celldex Therapeutics, Inc. - President, CEO, Director, Founder

Sure. So barzo is currently in two Phase-2 studies, one in chronic spontaneous urticaria, and the other in CindU or chronic inducible urticaria. The Phase-2 studies are currently enrolling. We also have completed a Phase 1b PN study, and that we are planning to put that into Phase 2 sometime later this year or the early part of '24.

The EoE study just initiated the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot